Safety of secukinumab in the treatment of patients with axial spondyloarthritis and concurrent hepatitis B virus infection or latent tuberculosis infection

S Liu, Z He, W Wu, H Jin, Y Cui - Clinical Rheumatology, 2023 - Springer
Objective To evaluate the safety of secukinumab (SEC) in the treatment of patients with axial
spondyloarthritis (axSpA) and concurrent hepatitis B virus (HBV) infection or latent …
被引用次数：4 相关文章

Safety of secukinumab in the treatment of patients with axial spondyloarthritis and concurrent hepatitis B virus infection or latent tuberculosis infection.

S Liu, Z He, W Wu, H Jin, Y Cui - Clinical Rheumatology, 2023 - search.ebscohost.com
Objective: To evaluate the safety of secukinumab (SEC) in the treatment of patients with
axial spondyloarthritis (axSpA) and concurrent hepatitis B virus (HBV) infection or latent …

Safety of secukinumab in the treatment of patients with axial spondyloarthritis and concurrent hepatitis B virus infection or latent tuberculosis infection.

S Liu, Z He, W Wu, H Jin, Y Cui - Clinical Rheumatology, 2023 - europepmc.org
Objective To evaluate the safety of secukinumab (SEC) in the treatment of patients with axial
spondyloarthritis (axSpA) and concurrent hepatitis B virus (HBV) infection or latent …

Safety of secukinumab in the treatment of patients with axial spondyloarthritis and concurrent hepatitis B virus infection or latent tuberculosis infection

S Liu, Z He, W Wu, H Jin, Y Cui - Clinical rheumatology, 2023 - pubmed.ncbi.nlm.nih.gov
Objective To evaluate the safety of secukinumab (SEC) in the treatment of patients with axial
spondyloarthritis (axSpA) and concurrent hepatitis B virus (HBV) infection or latent …